Condition: T Cell Malignancies · Sponsor: Electra Therapeutics Inc.
This is a Phase 1, two-part, multicenter study to evaluate ELA026 in participants ≥18 years old with relapsed/refractory TCM following any line of prior therapy who are eligible for investigational treatments.
This description comes directly from the study's public registry record.
Clinical Trials Electra Clinical Trials Information · Please email · clinicaltrials@electra-therapeutics.com
Always discuss trial participation with your own doctor first.
| Yale New Haven Hospital | New Haven, Connecticut, United States | Recruiting |
| Emory University Hospital | Atlanta, Georgia, United States | Recruiting |
| START, Midwest | Grand Rapids, Michigan, United States | Recruiting |
| Memorial Sloan Kettering | New York, New York, United States | Recruiting |
| University Hospitals Cleveland Medical Center | Cleveland, Ohio, United States | Recruiting |
| MD Anderson | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07465835